What happens when segments of the population are not included in clinical trials, especially when certain diseases disproportionally affect one gender or race over another? How do we really know how effective our medications are in the real world if a certain group isn’t part of the statistics? There’s growing evidence that, whether for environmental or genetic reasons, medications could have different effects based on race, ethnicity, and/or gender. This crucial conversation will shed light on the lack of diversity in clinical trials, addressing the gap, how this affects patients, and how to work together to increase enrollment for the best outcomes.